Patritumab deruxtecan is named as an intervention in 15 current clinical trials in our USA, China and UK registers. 11 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Merck Sharp & Dohme LLC (10). The most-studied condition is Breast Neoplasms.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Neoplasms | 3 |
| Breast Cancer | 2 |
| Gastroesophageal Junction | 2 |
| Gastroesophageal Adenocarcinoma | 2 |
| Esophageal Neoplasms | 2 |
| Esophageal Cancer | 2 |
| Non-Small Cell Lung Cancer (NSCLC) | 2 |
| Non-Small Cell Lung Cancer Metastatic | 1 |
| Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | 1 |
| Malignant Neoplasm | 1 |
| Nonsquamous Non-small Cell Lung Cancer | 1 |
| EGFR L858R | 1 |
| EGFR Exon 19 Deletion | 1 |
| Gastrointestinal Cancer | 1 |
| Lung Neoplasm Malignant | 1 |
| Advanced Solid Tumor | 1 |
| Melanoma | 1 |
| Head and Neck Cancer | 1 |
| Gastric Cancer | 1 |
| Non-small Cell Lung Cancer | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 10 |
| Daiichi Sankyo | 5 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 15 | 11 |
| Clinical trials in China | 8 | 6 |
| Clinical trials in UK | 6 | 4 |
A trial with sites in more than one country appears in each of those registers.
15 current trials in our USA, China and UK registers name Patritumab deruxtecan (also registered as U3-1402) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 11 of the 15 trials are recruiting: 11 with sites in USA, 6 with sites in China and 4 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Merck Sharp & Dohme LLC (10) and Daiichi Sankyo (5). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Patritumab deruxtecan works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Patritumab deruxtecan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Patritumab deruxtecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.